NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders.
Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million).
Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
email article
Hypofractionated ablative radiation therapy (RT) following standard chemotherapy was associated with durable tumor control and impressive survival outcomes for patients with locally advanced, inoperable pancreatic cancer in a retrospective single-center study.
From 2016 to 2019, median overall survival (OS) in more than 100 patients receiving ablative RT at a biologically effective dose of 98 Gy reached 18.4 months from the time of RT and 26.8 months from the time of initial diagnosis, reported Christopher Crane, MD, and colleagues from Memorial Sloan Kettering Cancer Center in New York City.
The 1- and 2-year OS rates from the time of ablative RT were 74% (95% CI 66-83%) and 38% (95% CI 27-52%), according to the findings in
E-Mail
PHILADELPHIA (March 12, 2021) - The biennial award honors the best scholarly qualities that Dr. Fagin, the School s third Dean, exemplified. It is given to a Penn Nursing faculty member, or a graduate from the School s doctoral program, who has made a distinguished contribution to nursing scholarship. Dr. Bruner will deliver the lecture Inspiration, Innovation and Impact virtually during the award presentation on April 15, 2021 from 3-4:30 PM EST.
Deborah Watkins Bruner, RN, PhD, FAAN, is Senior Vice President for Research at Emory University in Atlanta, Georgia. Bruner is also Professor and Robert W. Woodruff Chair in Nursing, Professor of Radiation Oncology, and a member of the Winship Cancer Institute. She is an internationally renowned researcher and clinical trialist with a focus on patient reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities.